Big Investor Watch
Hights Capital Management Cuts Stake in Reprocell (4978) to 5.95% | Large Shareholding Report
Activist InvestorSell

Hights Capital Management Cuts Stake in Reprocell (4978) to 5.95% | Large Shareholding Report

Stock
リプロセル (4978) — holding history (Japanese)
Deal date
Deal size
¥420M
Filer
ハイツ・キャピタル・マネジメント・インク

A large shareholding report (EDINET filing) shows that Hights Capital Management Inc. has reduced its stake in Reprocell (4978) to 5.95%. This represents a divestment by a U.S. biotech and healthcare-focused concentrated investment fund. Reprocell is a biotech venture company engaged in research and development as well as manufacturing and marketing of pharmaceutical products and regenerative medicine products using stem cells. The fund's 5.95% stake represents a significant shareholding position accounting for a material portion of the company's market capitalization.

The report is a change notification, revealing that the stake has declined by 2.75 percentage points from the previous disclosure. The estimated sale amount stands at ¥420 million.

*Speculation: The partial divestment by a concentrated investment fund focused on biotech ventures may suggest a staged position adjustment amid heightened market risk concerns regarding the stock.

Deal size is an estimate (shares outstanding × share price × change in holding ratio); EDINET filings do not state a yen amount. This article is generated from the filing's facts and is not investment advice. Read the Japanese edition of this article for the latest data.

Related articles